Takeda reported that zasocitinib, its oral TYK2 inhibitor for plaque psoriasis, beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. The company said zasocitinib induced complete elimination of skin lesions in more than a third of participants at 16 weeks, outperforming Sotyktu on primary and secondary goals. Takeda acquired zasocitinib from Nimbus Therapeutics for $4 billion upfront and has been running a series of high-stakes studies to establish its commercial potential against injectable biologics and an increasingly crowded oral segment. Bristol Myers’ Sotyktu, the first approved TYK2 inhibitor, has faced slower momentum in psoriasis, with analysts and management pointing to prescriber preferences for higher efficacy formats and concerns about oral efficacy profiles. Takeda’s results aim to shift that balance. The immediate industry impact is competitive: an oral efficacy gap could affect prescribing behavior ahead of broader launches, while reinforcing the payers’ and clinicians’ scrutiny on real-world comparative outcomes across administration routes.